Imunon, Inc. (IMNN)
Market Cap | 11.66M |
Revenue (ttm) | n/a |
Net Income (ttm) | -18.85M |
Shares Out | 9.40M |
EPS (ttm) | -2.02 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 11,432 |
Open | 1.250 |
Previous Close | 1.260 |
Day's Range | 1.240 - 1.326 |
52-Week Range | 0.480 - 2.000 |
Beta | 2.08 |
Analysts | Strong Buy |
Price Target | 12.00 (+867.74%) |
Earnings Date | Aug 8, 2024 |
About IMNN
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-vira... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for IMNN stock is "Strong Buy" and the 12-month stock price forecast is $12.0.
News
![](https://cdn.snapi.dev/images/v1/x/u/press11-2492669.jpg)
IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer
Novel IL-12 Immunotherapy Administered with Standard of Care as First-Line Treatment Expects topline results by the end of July LAWRENCEVILLE, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NAS...
![](https://cdn.snapi.dev/images/v1/c/i/press13-2463518.jpg)
First Participants Vaccinated in IMUNON's IMNN-101 Phase 1 Clinical Trial
DNA vaccine proof-of-concept study expected to demonstrate an “mRNA better” platform LAWRENCEVILLE, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company focuse...
![](https://cdn.snapi.dev/images/v1/d/i/press2-2431980.jpg)
Abstract on Phase 2 Study with IMUNON's IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting
LAWRENCEVILLE, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-genera...
![](https://cdn.snapi.dev/images/v1/s/h/press10-2426985.jpg)
IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
Proof-of-concept study for Imunon's first vaccine utilizing its proprietary PlaCCine platform is now open for enrollment
![](https://cdn.snapi.dev/images/v1/z/d/press9-2426708.jpg)
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J.
![](https://cdn.snapi.dev/images/v1/4/m/press15-2417840.jpg)
IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO
Assumes leadership role as Company anticipates multiple near-term clinical milestones Brings extensive leadership and experience in drug development and business strategy LAWRENCEVILLE, N.J., May 08, ...
![](https://cdn.snapi.dev/images/v1/n/w/conf6-2412463.jpg)
IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024
LAWRENCEVILLE, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vacci...
![](https://cdn.snapi.dev/images/v1/d/t/press5-2378040.jpg)
IMUNON's IND Application Cleared to Begin Human Testing of IMNN-101
Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in the second quarter
![](https://cdn.snapi.dev/images/v1/j/j/press14-2366994.jpg)
IMUNON Reports Compliance with Nasdaq Listing Requirements
LAWRENCEVILLE, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) (“IMUNON” or the “Company”), a clinical-stage drug-development company focused on developing DNA-mediated immuno-on...
![](https://cdn.snapi.dev/images/v1/9/b/press11-2345971.jpg)
IMUNON Reports 2023 Financial Results and Provides Business Update
Conference Call Begins Today at 10:00 a.m. Eastern Time LAWRENCEVILLE, N.J.
![](https://cdn.snapi.dev/images/v1/0/f/press18-2339653.jpg)
IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses
Non-dilutive funding strengthens balance sheet and extends current operating runway LAWRENCEVILLE, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-developm...
![](https://cdn.snapi.dev/images/v1/6/x/conf8-2336431.jpg)
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024
LAWRENCEVILLE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vac...
![](https://cdn.snapi.dev/images/v1/m/m/press12-2321945.jpg)
IMUNON Files IND Application to Begin Human Testing of IMNN-101
Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2 The application follows guidance provided to IMUNON in Pre-IND meeting with the FDA
![](https://cdn.snapi.dev/images/v1/n/o/press19-2321084.jpg)
IMUNON Announces Leadership Change
Executive Chairman to lead day-to-day operations, active search underway for CEO successor.Timing of upcoming milestones for key programs remains unchanged.
![](https://cdn.snapi.dev/images/v1/j/d/press5-2301000.jpg)
Independent Lab Confirms Immunogenicity and Protection with IMUNON's IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5
Murine Study by the Wistar Institute Builds Upon Favorable Results Previously Reported by IMUNON With its Prototype PlaCCine Vaccine Modality
![](https://cdn.snapi.dev/images/v1/c/m/press11-2295727.jpg)
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON's IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
Trial will evaluate the effect of this combination therapy on minimal residual disease LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-develop...
![](https://cdn.snapi.dev/images/v1/h/w/press11-2288331.jpg)
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine
Data Show Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccine Modality LAWRENCEVILLE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage dr...
![](https://cdn.snapi.dev/images/v1/w/0/press4-2191000.jpg)
IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Accomplished pharmaceutical and biotechnology executive to lead IMUNON's clinical programs in ovarian cancer and infectious diseases
![](https://cdn.snapi.dev/images/v1/l/m/conf19-2156923.jpg)
IMUNON's VP of R&D to Present at the Vaccines Summit-2023
Dr. Jean Boyer to highlight updated data showing the advantages of IMUNON's PlaCCine modality and its applicability to multiple pathogens
![](https://cdn.snapi.dev/images/v1/1/j/press17-2156634.jpg)
IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update
Advances Non-Viral DNA-Mediated Cancer Immunotherapy and Next-Generation Vaccine Programs, with More Potent and Durable Immunity, with Multiple Near-Term Milestones
![](https://cdn.snapi.dev/images/v1/t/0/conf11-2143882.jpg)
IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023
LAWRENCEVILLE, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vacc...
![](https://cdn.snapi.dev/images/v1/5/4/conf3-2115108.jpg)
IMUNON's Chief Science Officer to Present at the 3rd International Vaccines Congress
Highlights advantages of IMUNON's PlaCCine modality over current commercial vaccines LAWRENCEVILLE, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage biotechnology...
![](https://cdn.snapi.dev/images/v1/m/n/press14-2110952.jpg)
IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United Nations
“ A Tale of Two Pandemics: Lessons From the 1889 & 2019 Pandemics” presented by the Foreign Policy Association
![](https://cdn.snapi.dev/images/v1/5/5/press18-2108621.jpg)
IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer
The MRD trial will evaluate the effect of this treatment combination on minimal residual disease. LAWRENCEVILLE, N.J.
![](https://cdn.snapi.dev/images/v1/c/z/press10-2093021.jpg)
IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board
Renowned Daner-Farber Cancer Institute researcher will advise on the development of IMUNON's FixPlas™ and Indiplas™ modalities in immuno-oncology.